Wellma
Wellma is a European contract development and manufacturing organization (CDMO) that develops, formulates, and produces nutraceuticals and niche pharmaceuticals across all major formats for B2C brand owners. It operates a 15-site federation across seven European countries unified by GFSI-aligned certifications.
- Company typePrivate
- Founded2021
- HeadquartersStockholm, Sweden
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Wellma does
Wellma is a European contract development and manufacturing organization (CDMO) serving B2C nutraceutical brands and pharmaceutical companies. Founded in 2021 and headquartered in Stockholm (registered as Wellma Group AB), the company operates a federation of 15+ specialized development and manufacturing sites across Sweden, the UK, the Netherlands, Italy, Spain, Germany, and Denmark, each retained under its acquired brand and led by its founding managing director. The platform covers the full nutraceutical format spectrum — tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating and granulation, and liposomal technology — and is unified by GFSI-aligned certifications (FSSC 22000, IFS Food, BRCGS, cGMP) plus FDA, GACC, and ISO 56001 certifications.
The company makes money by selling formulation, development, production, packaging, and regulatory-support services to nutraceutical and pharmaceutical brand owners, with quote-based pricing and unit MOQs ranging from 80 kg (coating) to 300 kg (gummies) to 100,000 tablets. Service breadth spans R&D (e.g., NutraResearch), specialty actives (PlantaCorp's liposomal encapsulation), and high-volume manufacturing (e.g., Euronovis coating ~800 million tablets per year). Go-to-market is sales-led and direct, supported by LinkedIn presence, content marketing, and participation in industry trade shows such as Vitafoods Europe.
Reported sales scaled from over €50M (Feb 2024) to €120M+ (Apr 2025), a trajectory driven primarily by 8 acquisitions completed between August 2023 and October 2025. Subsidiaries include Legosan, Euronovis, Pouch Alliance, Calleva, MixMasters, NutraResearch, Nutrifundiet, Private Label Factory, PlantaCorp, The Bar Factory, and Fipros A/S, serving a long-tail of 150+ global brand customers across the nutraceutical and pharmaceutical sectors.
Wellma firmographics
Firmographics- Name
- Wellma
- Legal name
- Wellma Group AB
- Website
- https://wellma.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Wellma is a European contract development and manufacturing organization (CDMO) that develops, formulates, and produces nutraceuticals and niche pharmaceuticals across all major formats for B2C brand owners. It operates a 15-site federation across seven European countries unified by GFSI-aligned certifications.
- Ownership category
- akta.pro rank
Wellma industry classification
Industry- Product category
- Contract Development and Manufacturing (CDMO) for Nutraceuticals and Pharmaceuticals
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Wellma is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Wellma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services: Wellma generates revenue through providing development and manufacturing services to B2C brands in the nutraceutical and pharmaceutical space. Services span from formulation to production, packaging, and regulatory support across all product formats. The company operates through an ecosystem of specialized manufacturing sites across Europe.
- CDMO Services Revenue: Revenue from contract manufacturing organization services, with the company reporting €70M+ in sales (2023) growing to €100M+ (2024) and €120M+ (2025), indicating consistent growth in manufacturing service revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Wellma product offering
Product offeringCore offering
Wellma is a European Contract Development and Manufacturing Organization (CDMO) platform serving the nutraceutical and pharmaceutical industries. The company provides end-to-end services spanning R&D, formulation, production, packaging, and regulatory support across all major product formats (tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating, granulation, pellets), delivered through an ecosystem of 15+ specialized manufacturing sites across Europe that each retain entrepreneurial leadership and deep format-specific expertise.
Product overview
Wellma is a European development and manufacturing partner (CDMO) for nutraceuticals and pharmaceuticals. The company operates a platform model combining specialized manufacturing sites across Europe under unified quality standards. The product portfolio includes core format capabilities: Tablets, Capsules, Powder, Gels, Liquids, Gummies, Bars, Softgels, Coating/Granulation/Pellets, and Special Liposomal Technology. Wellma has acquired/partnered with specialized companies including Legosan (Sweden - tablets/capsules), Calleva (UK - nutraceutical ingredients/gels), MixMasters (Netherlands - powders), Euronovis (Italy - coating/granulation), NutraResearch (Spain - R&D/liquids/solids), Nutrifundiet (Spain - gummies), Pouch Alliance (Netherlands - liquids/gels), Private Label Factory (Germany - digital manufacturing), PlantaCorp (Germany - liposomal technology), Fipros A/S (Denmark - gels/powders), and The Bar Factory (Netherlands - bars). Services span full product lifecycle from R&D, formulation, production, packaging, and regulatory support. The ecosystem enables cross-site collaboration to serve global customers with comprehensive format capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Tablet Manufacturing Contract manufacturing of tablets for both nutraceuticals and pharmaceuticals, with wide diversity in shape and dissolution characteristics. Applications include multivitamins, probiotics, weight management, and herbal supplements. Packaging options include bottling, blistering, labeling with eco-friendly options. MOQ: 100k tablets.
- Capsule Manufacturing Contract manufacturing of capsules including vegan HPMC, gelatin, and acid-resistant variants in all sizes and applications. Designed for aesthetics, ease of swallowing, and taste-masking capabilities. MOQ: 500 bottles.
- Powder Manufacturing Contract manufacturing of unique tailored or standard powder recipes with unmatched flavoring capabilities. Products include pre-workouts, energy boosters, meal shakes, plant-based proteins, whey protein, and amino acids. Packaging in sachets, jars, pouches, and bags from 10g to 20kg. MOQ: 250 kg.
- Gel Manufacturing Contract manufacturing of nutritional gels including energy gels, protein gels, isotonic gels, vitamin and mineral shots, syrups, and liquid supplements. On-the-go, fast-acting formats ideal for sports and active nutrition applications. Packaging in single-serve flexible packs, tubes, and spouted stand-up pouches.
- Liquid Manufacturing Contract manufacturing of liquid food supplements and functional beverages with custom formulations and excellent taste profiles. Includes vials, sprays, and drops with highly bioavailable shots and syrups for complex formulations. Packaging in single-serve flexible packs, tubes, vials, and stand-up pouches.
- Gummy Manufacturing Contract manufacturing of nutraceutical gummies with customizable shapes and wide formulation capabilities including jelly bars. Vegan, sugar-free, and allergen-free options available. Bottling and labeling including eco-friendly options. MOQ: 300 kg.
- Bar Manufacturing Contract manufacturing of functional protein and energy bars for on-the-go nutrition with tailored flavor and function from energy to protein applications.
- Softgel Manufacturing Contract manufacturing of high-absorption softgel format for oils and fat-soluble actives. Available in vegan, fish, and beef gelatins in oval and oblong shapes.
- Coating, Granulation and Pellet Services Advanced contract coating, granulation, and pellet production services that adjust release patterns, mask unpleasant tastes, and improve shelf-life. Specialized facility exclusively focused on coating, granulation, and pellets. MOQ: 80 kg.
- Liposomal Technology R&D and Manufacturing
Quantifiable outcome
- Revenue growth from €70M+ (2023) to €120M+ (2025)
- +3 more outcomes
Companies that use Wellma
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles5 records
Wellma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Wellma partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Fipros A/ScoreFipros A/S, a Danish CDMO specialized in powders and gels, joined Wellma. Founded in 1992 and headquartered in Funen, Denmark, the company operates from two sites and serves more than 150 customers globally. The company brings advanced automation and robotics capabilities developed over three decades.
- The Bar FactorycoreThe Bar Factory, a Dutch CDMO specialized in development and production of high-quality functional protein and energy bars, joined Wellma. Based in Duiven, Netherlands, the company focuses on formulation and production of premium bars known for superior taste, texture, and nutritional profile. This partnership expands Wellma into the functional bars segment.
- PlantaCorpcorePlantaCorp, a German CDMO and leading innovator in liposomal technology for liquid formulations, partnered with Wellma. Based in Hamburg, Germany, PlantaCorp is known for cutting-edge R&D and proprietary liposomal encapsulation technology that enhances bioavailability of active ingredients.
- NutraResearchcoreNutraResearch, a Barcelona-based R&D center and CDMO supporting development and production of nutraceutical products in liquid (vials, sprays, drops) and solid (tablets, capsules, powder) forms, joined Wellma. Renowned for advanced R&D capabilities and groundbreaking technological platform for next-generation food supplements.
- NutrifundietcoreNutrifundiet, a niche-focused developer and manufacturer for nutraceutical gummies based in Ávila near Madrid, Spain, joined Wellma. IFS certified plant with exceptional formulation capabilities and dedication to high-quality gummy supplements including vegan, sugar-free, and allergen-free options.
- WestcottsminorWestcotts, a business advisory firm, facilitated the merger between Calleva and Wellma, representing Wellma's entry into the UK and European markets. The deal aligned interests of both parties and was structured to support future growth and expansion.
- CallevacoreCalleva, a UK-based specialist in development and manufacturing of nutraceutical ingredients and products in nutritional gels, powder, and purpose-built ingredients, merged with Wellma. Based in Bridgwater, UK, Calleva brings capabilities in formulations, sourcing, excellent taste profiles, and BRC-certified manufacturing standards. This marked Wellma's entry into the UK market and first acquisition outside the EU.
- Pouch AlliancecorePouch Alliance, a Dutch specialist in development and manufacturing of nutritional liquids and sport gels, joined Wellma. Based in Wormer, Netherlands, Pouch Alliance is a leader in formulating, producing, and packaging nutritional liquids including energy gels, vitamin/mineral shots, protein gels, isotonic gels, syrups, and liquid supplements with BRC Global Standard certification.
- PLF-Legosan CollaborationminorPrivate Label Factory (Germany) partnered with Legosan (Sweden) within the Wellma ecosystem to fulfill a large tablet order for a major retail client, demonstrating cross-site collaboration capabilities within Wellma's network.
- EuronoviscoreEuronovis, an Italian coating and granulation specialist, became part of Wellma. Established in 2015 and based near Milan, Euronovis offers services for coating, granulation, pellet production, consultation, and formulation. Has capacity to coat over 800 million tablets per year and serves 40+ customers from 1,500 sqm cleanroom facility.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Wellma competitors and assessment
Company assessmentBroad incumbents
- Lonza: Swiss global CDMO leader across small molecules, biologics, and cell & gene therapy with a consumer health and nutrition segment. A scaled incumbent whose breadth dwarfs Wellma but who participates in the same end-markets.
- Catalent: Global CDMO (now under Novo Holdings) with broad pharma and consumer health services including softgel, oral, and biologics capabilities. Much larger and broader than Wellma, but competes for the same mid-market brand customers.
Direct peers
- Martin Bauer Group: German family-owned supplier of botanical extracts, tea, and plant-based ingredients serving the nutraceutical and beverage industries. Comparable European specialist serving brand customers in supplements and functional beverages.
- Glatt Group: German family-owned group providing process technology, CDMO services, and integrated plant engineering for pharma, food, and nutraceutical applications including tablet coating and granulation — directly overlapping Euronovis's niche.
- Delpharm: French-headquartered pan-European CDMO with manufacturing sites across France, Italy, Netherlands, and Canada, providing contract development and manufacturing for pharma and consumer health. Comparable multi-site, multi-country CDMO model.
- Hermes Arzneimittel: German pharmaceutical manufacturer with significant consumer healthcare and OTC manufacturing capabilities, including effervescents and granulates. Comparable mid-sized European CDMO/CMO for brand customers.
- Recipharm: Swedish-headquartered European CDMO offering development and manufacturing services for pharmaceuticals and complex formulations across multiple dosage forms. Closest geographic and structural peer to Wellma, though Recipharm is much larger and more pharma-weighted.
- Aenova: Germany-based leading European CDMO for pharmaceuticals and nutraceuticals with broad format coverage including solids, semi-solids, liquids, and sterile products. Competes with Wellma for the same B2C brand customers across multiple formats.
Emerging players
- BIOIBERICA: Spanish life science company specializing in bioactive ingredients for nutraceutical and pharma applications, with CDMO-like manufacturing capabilities. Comparable European focus on nutraceutical ingredients and formulations.
Regional players
- Alcami Corporation: US-headquartered CDMO offering sterile fill-finish, oral solids, and analytical services. Comparable CDMO model but focused on the US market; relevant benchmark for CDMO service pricing and operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Wellma social profiles
Digital presenceWellma compliance and trust
Trust signalCompliance9 records
Wellma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wellma leadership team
Management profileNumber of profiles
Profiles14 records
Wellma subsidiaries and ownership
Company hierarchySubsidiaries11 records
Wellma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wellma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wellma
What does Wellma do?
Wellma is a European Contract Development and Manufacturing Organization (CDMO) platform serving the nutraceutical and pharmaceutical industries. The company provides end-to-end services spanning R&D, formulation, production, packaging, and regulatory support across all major product formats (tablets, capsules, powders, gels, liquids, gummies, bars, softgels, coating, granulation, pellets), delivered through an ecosystem of 15+ specialized manufacturing sites across Europe that each retain entrepreneurial leadership and deep format-specific expertise.
Is Wellma a public or private company?
Wellma is a private company. It is classified as unknown and is currently operating.
When was Wellma founded?
Wellma was founded in 2021. It employs 101 to 250 people.
Where is Wellma based?
Wellma is headquartered in Stockholm, Sweden, in the Europe region.
How does Wellma make money?
Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are CDMO Services Revenue.
Who are Wellma's main competitors?
Broad incumbents on record are Lonza and Catalent. Direct peers are Martin Bauer Group, Glatt Group, Delpharm, Hermes Arzneimittel, Recipharm and Aenova. BIOIBERICA is listed as an emerging player. Alcami Corporation is listed as a regional player.
Does Wellma have an API?
No public API is recorded for Wellma.
What industry is Wellma in?
Wellma's product category is Contract Development and Manufacturing (CDMO) for Nutraceuticals and Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 5417 and its SIC code is 8731.